US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
pharma · Acquired Blepharoptosis · Diabetic Macular Edema
Santen Oy
Santen Oy drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
TAMPERE, FI HQ
15 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- TAMPERE, FI
- Employees
- 15
- Programs
- 3
- Drugs
- 8
- Patents
- 0
Santen Oy pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Santen Oy drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Santen Oy in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Santen Oy in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Adrenergic receptor alpha agonist.
- Mechanism
- Adrenergic receptor alpha agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha.
- Target
- Adrenergic receptor alpha
- Mechanism
- Adrenergic receptor alpha agonist
-
Development asset linked to Santen Oy in public FDA and regional records.
-
Development asset linked to Santen Oy in public FDA and regional records.